0 CHECKOUT

Investigation Report on China Adalimumab Market, 2010-2018

  • ID: 2770934
  • March 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

FEATURED COMPANIES

  • AbbVie
  • BASF Pharma
  • Huahai Pharmaceutical
  • MORE

Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.

As of 2008 adalimumab (produced by Abbott with the trade name ""Humira"") had been approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Adalimumab is the best seller in the world in recent years. It can satisfy many urgent clinical needs because of its wide range of indications. The global sales revenue of Humira in 2012 exceeded USD 9 billion, and it reached USD 10 billion in 2013. Humira was launched in China in August 2010. According READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • BASF Pharma
  • Huahai Pharmaceutical
  • MORE

1 Relevant Concepts of Adalimumab
1.1 Development Process and Indication
1.2 Sales Status on the Global Market

2 Market Overview of Adalimumab in China, 2010-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Adalimumab in China, 2010-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013

5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013

6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013

7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013

8 Prospect of China Adalimumab Market, 2014-2018
8.1 Prospect of Adalimumab Indication Group
8.2 Manufacturing Schedule of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern

Selected Charts

Chart Adalimumab Products Approved to Market in China, 2014
Chart Forecast on Market Size of Hospital-use Adalimumab in China, 2014-2018
Chart Global Sales Value of Adalimumab, 2010-2013
Chart Sales Value of Adalimumab in China Hospital Market, 2010-2013
Chart Sales Value of Adalimumab by Region in China, 2010-2013
Chart Market Share of Adalimumab in China, 2010-2013
Chart Price of Adalimumab Produced by GENENTECH (US) in Hospital Market, 2010-2013
Chart Price of Adalimumab Produced by Shanghai Roche in Hospital Market, 2010-2013

Note: Product cover images may vary from those shown

- AbbVie
- BASF Bioresearch Corporation
- BASF Pharma
- Huahai Pharmaceutical

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S